Inductors of microsomal liver enzymes (phenytoin, barbiturates, carbamazepine, flumecinol, rifampicin, phenylbutazone, tricyclic antidepressants, zidovudine and others), ethanol, hepatotoxic drugs increase the risk of developed hepatotoxic effects of paracetamol.
Inhibitors of microsomal oxidation (cimetidine) reduce the risk of hepatotoxic effects. When taking concomitantly with salicylates, the likelihood of developing a nephrotoxic effect increases.
When combined with paracetamol, the toxic effects of chloramphenicol are enhanced. Paracetamol strengthens the effect of methotrexate, m-holinoblokatorov, antidepressants (sedative effect), anticoagulants of indirect action (increased prothrombin time), systemic corticosteroids (increases the risk of ulcerogenic effects), oral hypoglycemic agents (blood sugar is lowered); reduces the effectiveness of uricosuric drugs and lisinopril. Paracetamol reduces the absorption of tetracyclines (the interval between doses should be at least 2 hours) and accelerates the excretion of lamotrigine.
With the combined use of paracetamol with MAO inhibitors, a sudden increase in blood pressure may occur, and in combination with organic nitrates, it may drop dramatically.
When combined with activated charcoal, antacid and anticholinergic agents, the absorption and effectiveness of paracetamol is reduced, and its absorption also decreases with the administration of colestyramine (with an interval of less than one hour between doses). Metoclopramide increases the absorption of paracetamol (it is also possible to increase its concentration in the blood plasma). Oral contraceptives accelerate the excretion of paracetamol and reduce its analgesic effect, and ethinyl estradiol increases its absorption from the intestine.
Long-term use of barbiturates reduces the effectiveness of paracetamol.
Diflunisal increases the plasma concentration of paracetamol by 50% - the risk of developing hepatotoxicity. Myelotoxic drugs increase the manifestation of hematotoxicity of the drug.